TScan Therapeutics (TCRX) Stock Forecast & Price Target

TScan Therapeutics is positioned positively due to the significant clinical results of its T-cell receptor engineered therapies, TSC-100 and TSC-101, which demonstrated a 70% improvement in event-free survival and a notably low relapse rate of 8% in the treatment arm compared to 33% in the control group. The company’s recent FDA clearance for an additional MAGE-A4 TCR further enhances its portfolio and expands patient eligibility, particularly for non-small cell lung cancer, as it continues to grow its ImmunoBank for multiplex TCR-T therapies. TScan's focus on addressing both hematologic malignancies and solid tumors provides a robust pathway for long-term value creation in large market segments, supported by ongoing clinical studies and a clear trajectory toward pivotal study approvals.

TScan Therapeutics Inc. reported a significant net loss of $35.8 million in 4Q24, up from $19.6 million in the same quarter the previous year, indicating worsening financial performance. The company's bear case scenario projects a 45% decrease in the probability of success for its hematological malignancy candidates if upcoming clinical updates reveal multiple patient relapses. Furthermore, concerns exist regarding the company’s ability to develop additional successful clinical candidates beyond its current programs, contributing to a cautious outlook on its financial future.